Search alternatives:
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
highest increase » highest incidence (Expand Search), slight increase (Expand Search)
higher decrease » higher degree (Expand Search), higher degrees (Expand Search)
significant decrease » significant increase (Expand Search), significantly increased (Expand Search)
highest increase » highest incidence (Expand Search), slight increase (Expand Search)
higher decrease » higher degree (Expand Search), higher degrees (Expand Search)
-
121
-
122
Summary of post-treatment disease course measures from MDMA-AT publications.
Published 2025Subjects: -
123
-
124
Summary of post-treatment CAPS score changes from clinical trials with FDA-approved medications.
Published 2025Subjects: -
125
-
126
-
127
-
128
Summary of post-treatment disease course measures from off-label medications clinical trials.
Published 2025Subjects: -
129
Summary of post-treatment CAPS score changes from clinical trials with psychotherapies.
Published 2025Subjects: -
130
Summary of clinical studies of FDA-approved medications for PTSD: Disease course outcomes.
Published 2025Subjects: -
131
Summary of post-treatment disease course measures from clinical trials with psychotherapies.
Published 2025Subjects: -
132
-
133
-
134
Post-treatment CAPS score changes from clinical trials with off-label PTSD medications.
Published 2025Subjects: -
135
Metabolites with decreasing levels during the development.
Published 2025“…<p>Temporal profiles of polar metabolites and lipids with SCN levels significantly decreasing from E19 to P28. Rhythmicity was determined by eJTK; full or dashed lines depict the profiles that either did or did not pass the significance threshold (FDR-adjusted <i>P</i> < 0.05), respectively.…”
-
136
-
137
-
138
-
139
-
140